Seagen Inc. (SGEN) News
Filter SGEN News Items
SGEN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SGEN News Highlights
- For SGEN, its 30 day story count is now at 8.
- Over the past 15 days, the trend for SGEN's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- DRUG, WASH and ADC are the most mentioned tickers in articles about SGEN.
Latest SGEN News From Around the Web
Below are the latest news stories about SEAGEN INC that investors may wish to consider to help them evaluate SGEN as an investment opportunity.
PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder CancerAstellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced that on December 15, 2023 the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin-ejfv, an antibody-drug conjugate [ADC]) with KEYTRUDA® (pembrolizumab, a PD-1 inhibitor) for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/mUC). This combination is the first approved to offer an alternative to platinum-con |
3 Stocks That Are About to Get Absolutely CrushedThese are a few different companies that are experiencing difficult times and that are expected to keep falling. |
3 Sleepy Stocks Ready to Wake up in 2024Strong projected earnings growth makes these three stocks strong candidates for exceptional growth in 2024. |
Big Pharma: Why the drug industry faces a 3-front battle with the FTC, Medicare, and the White HouseThe Biden administration is increasingly focused on finding ways to lower drug prices, putting the drug industry in a three-way battle to defend its ecosystem. |
We're Interested To See How Seagen (NASDAQ:SGEN) Uses Its Cash Hoard To GrowWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining... |
Illumina battles EU regulators over Grail dealIllumina (ILMN) seeks to resolve it's battle with EU regulators regarding acquisition of biotech company Grail. Earlier this year, Illumina received a $476 million fine from EU authorities over the deal. It comes as Pfizer (PFE) says it has received all the necessary regulatory approvals for its acquisition of Seagen (SGEN). Yahoo Finance's Anjalee Khemlani breaks down the biggest pharma stories of the day in the video above. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Click here to watch the full interview on the Yahoo Finance YouTube page or you can watch this full episode of Yahoo Finance Live here. |
ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin LymphomaBOTHELL, Wash., December 11, 2023--Seagen Inc. (NASDAQ: SGEN) today announced that clinically meaningful progression-free survival (PFS), a secondary endpoint, was observed in a Phase 2 study evaluating the antibody-drug conjugate (ADC) ADCETRIS® (brentuximab vedotin) in combination with the PD-1 inhibitor nivolumab and standard chemotherapy agents doxorubicin and dacarbazine (AN+AD) as first-line treatment for early and advanced stage classical Hodgkin lymphoma (cHL). This is the first time 12- |
3 Blue-Chip Stocks Set to Make a Comeback in 2024These are the blue-chip stocks to buy as they represent quality companies with a steady growth outlook and promising cash flow growth. |
TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast CancerBOTHELL, Wash., December 06, 2023--Seagen Inc. (Nasdaq: SGEN) today announced data from the Phase 3 HER2CLIMB-02 clinical trial of TUKYSA® (tucatinib) in combination with the antibody-drug conjugate ado-trastuzumab emtansine (Kadcyla®). The combination showed a statistically significant improvement in progression-free survival (PFS), the study’s primary endpoint, in patients with unresectable locally advanced or metastatic human epidermal growth factor receptor 2-positive (HER2-positive) breast |
Why Is Seattle Genetics (SGEN) Down 0.7% Since Last Earnings Report?Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |